Quotables
"I think there is a world market for maybe five computers."
Thomas Watson, chairman of IBM ; 1943
PatentStorm News
Make the Most of Our Site
See this month's Top Inventors and Most Cited Patents.
Stay on top of the latest innovations by subscribing to an RSS feed.
Registered users: Manage your profile.
| Number | Title | Issue Date |
| 7351826 | Aryl acid pyrimidinyl methyl amides, pyridazinyl methyl amides and related compounds The invention provides compounds of Formula (I) that bind to GABAA receptors. In the above formula, variables are defined herein. Such compounds may be used to modulate ligand binding to GABAA receptors in vivo or in vitro, and are particularly... | 04/01/2008 |
| 7291621 | Substituted biaryl amides C5a receptor modulators Substituted biaryl amides of Formula I are provided. Such compounds are ligands that may be used to modulate C5a receptor activity in vivo or in vitro, and are particularly useful in the treatment of conditions associated with pathological C5... | 11/06/2007 |
| 7122546 | Imidazol-1-ylmethyl pyridazine derivatives The invention provides imidazol-1-ylmethyl pyridazine derivatives of the formula: that bind to GABAA receptors. In the above formula, R1, R2 R3, R4, R5 | 10/17/2006 |
| 6953801 | Melanin concentrating hormone receptor ligands: substituted 1-benzyl-4-aryl piperazine analogues Melanin concentrating hormone receptor ligands (especially 1-benzyl-4-aryl-piperazines, 1-benzyl-4-aryl-piperidines and related compounds), capable of modulating MCH receptor activity, are provided. Such ligands may be used to modulate MCH binding to MCH receptors i... | 10/11/2005 |
| 6858637 | Substituted biaryl amides as C5a receptor modulators Substituted biaryl amides of Formula I are provided. Such compounds are ligands that may be used to modulate C5a receptor activity in vivo or in vitro, and are particularly useful in the treatment of conditions associated with pathological C5a receptor... | 02/22/2005 |
| 6723743 | High affinity small molecule C5a receptor modulators This invention relates to low molecular weight, non-peptidic, non-peptidomimetic, organic molecules that act as modulators of mammalian complement C5a receptors, preferably ones that act as high affinity C5a receptor ligands and also to such ligands that act as anta... | 04/20/2004 |
